Shots:

• The clinical research commences in NIH-led Adaptive COVID-19 Treatment Trial and will evaluate the efficacy and safety of baricitinib for hospitalized patients diagnosed with COVID-19- initiating this month in the US with a planned expansion to additional sites including EU and Asia
• Additionally- Lilly will advance its LY3127804 (mAb against Ang2) to P-II study for pneumonia patients hospitalized with COVID-19 who are at higher risk of ARDS with its expected initiation later this month in the US
• Baricitinib is an oral JAK1/JAK2 inhibitor with a brand name Olumiant and is an approved therapy in 65+ countries for moderately to severely active RA. The company does not anticipate any shortage for its therapies including baricitinib amid COVID-19

Click here ­to­ read full press release/ article 

Ref: Eli Lilly  | Image: Eli Lilly